Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ — Telix Prescribed drugs Restricted (ASX: TLX, NASDAQ: TLX, “Telix”) at present ...
